What changed recently
Newly published and updated guidelines across every system, newest first. Each entry links to the official source.
10 older updates are outside this window. Show all time
- Musculoskeletal & RheumatologyUS2026-06-242019 guideline → 2026 updateSpondyloarthritis
The 2026 revision of the 2019 adult guideline adds JAK inhibitors as a recommended option (a class absent from the previous version), keeps TNF and IL-17 inhibitors as the preferred first biologics, and advises against IL-23 inhibitors. It also broadens scope with new guidance on nociplastic pain, imaging strategy, bone health and comorbidities, and is accompanied by a first-ever companion guideline for juvenile axial spondyloarthritis.
- Musculoskeletal & RheumatologyEU2026-06-012022 update → 2025 updateRheumatoid arthritis
The task force consolidated the guidance from 11 recommendations down to 9 by merging and deleting items, while keeping methotrexate plus short-term glucocorticoids as the first step and adding a biologic DMARD after 3-6 months of inadequate response. Safety framing was sharpened, with JAK inhibitors requiring explicit assessment of cardiovascular and malignancy risk before use.
source ↗curation confidence 90%